A Phase IV Study in Drug-Naive Patients With T2DM in China
A phase 4 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 304 participants.
Also called NCT03344341
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 304 participants
- Sponsor
- Registry
-
NCT03344341
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- China
- Registry status
- Terminated
Technical summary
Registry record NCT03344341. Randomized; no masking; primary purpose treatment. Start 2017-12-15 (actual); primary completion 2019-05-24 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Phase IV Study in Drug-Naive Patients With T2DM in China
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- Dapagliflozin
- Intervention (Drug)
- Acarbose
- Lead sponsor
- AstraZeneca
Record details
- Record id
cardio:ct-nct03344341- Content hash
0242e3aed21ea83a4d59a3d8a61aa8784378b29a338a6b8484a36381503b0e7d